2-phenylbenzothiazole has been researched along with Cognition Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adlard, PA; Bray, L; Bush, AI; Cherny, RA; Doble, P; Finkelstein, DI; Gunawan, L; Hare, D; Lear, J; Sedjahtera, A | 1 |
| Langbehn, DR | 1 |
| Adlard, PA; Bush, AI; Doble, P; Finkelstein, DI; Hare, D; James, S; Lal, V; Parncutt, J | 1 |
| Bharti, K; Majeed, AB; Prakash, A | 1 |
| Bedo, J; Blennow, K; Bush, AI; Cummings, JL; Faux, NG; Gunn, A; Harrison, J; Herd, CM; Ingelsson, M; Lannfelt, L; Masters, CL; Rembach, A; Ritchie, CW; Tanzi, RE; Tsatsanis, A; Zetterberg, H | 1 |
2 trial(s) available for 2-phenylbenzothiazole and Cognition Disorders
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Biomarkers; Clioquinol; Cognition Disorders; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Placebos; Treatment Outcome | 2015 |
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Area Under Curve; Australia; Clioquinol; Cognition Disorders; Copper; Dose-Response Relationship, Drug; Double-Blind Method; Executive Function; Humans; International Cooperation; Ionophores; Neuropsychological Tests; Peptide Fragments; ROC Curve; Superoxide Dismutase; Superoxide Dismutase-1; Sweden; tau Proteins | 2010 |
4 other study(ies) available for 2-phenylbenzothiazole and Cognition Disorders
| Article | Year |
|---|---|
A novel approach to rapidly prevent age-related cognitive decline.
Topics: Aging; Animals; Behavior, Animal; Biomarkers; Cell Count; Clioquinol; Cognition Disorders; Dendritic Spines; Female; Glutamic Acid; Hippocampus; Maze Learning; Mice; Mice, Inbred C57BL; Neurogenesis; Neuronal Plasticity; Protein Phosphatase 2; Receptors, Glutamate; Synapses; Vesicular Glutamate Transport Protein 1; Zinc | 2014 |
Criteria for success in safety and tolerability trials.
Topics: Clioquinol; Cognition Disorders; Female; Humans; Huntington Disease; Male | 2015 |
Metal chaperones prevent zinc-mediated cognitive decline.
Topics: Analysis of Variance; Animals; Carrier Proteins; Cation Transport Proteins; Clioquinol; Cognition Disorders; Disease Models, Animal; Escape Reaction; Female; Gene Expression Regulation; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Male; Maze Learning; Membrane Proteins; Membrane Transport Proteins; Mice; Mice, Knockout; Patch-Clamp Techniques; Zinc | 2015 |
Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice.
Topics: Administration, Oral; Aging; Amyloid beta-Peptides; Animals; Clioquinol; Cognition Disorders; Dose-Response Relationship, Drug; Galactose; Injections, Subcutaneous; Male; Mice; Mice, Inbred Strains; Zinc Sulfate | 2016 |